Vtv Theraptcs Cl A (VTVT) Stock Price, Quote & News

Company Profile

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for t...

Industry: Biotechnology

Sector: Healthcare

Phone: 336 841 0300

Fax: 336 841 0310

Website: vtvtherapeutics.com

Address:

3980 Premier Drive, Suite 310, High Point, United States

Samiam69 Oct. 3 at 11:26 PM

$VTVT there goes the 650k float 🐢🐢🐢

0 · Reply

AStrokeOfLuck Oct. 3 at 8:52 PM

$VTVT

0 · Reply

Newtrader_covid19 Oct. 3 at 7:10 PM

$VTVT $VTVT finally break even. Holding this long before RS and 2026 phase 3 trial result will push this 5 fold. It’s already been above 3 years.I am positive it will return me Enough to pay off my mortgage 💪🏻

0 · Reply

Social_Idiot Oct. 2 at 2:13 PM

$VTVT I have to say that I find this stock attractive but between the low float and low volume, the volatility makes it hard to trust.

1 · Reply

Estockpicker Sep. 30 at 3:29 PM

$VTVT interesting stock. what is the catalyst that will drive this stock higher

1 · Reply

Mik21212 Sep. 26 at 6:44 PM

$VTVT in, glta

0 · Reply

dcajic2 Sep. 26 at 2:55 PM

$VTVT Reality land. There are well over 2 million shares outstanding plus if the 80 million investment goes through many more shares will be added

0 · Reply

GDS_investing Sep. 26 at 2:20 PM

$VTVT looking great and strong golden cross is in 50ma vs 200ma = huge long need more volume float only 640k

1 · Reply

outlawinvestor1 Sep. 25 at 9:36 PM

$VTVT

1 · Reply

km1663 Sep. 24 at 10:31 PM

$VTVT it will be interesting to see where the SP goes from here. Looks like a perfect cup has formed on the 6mo time frame.

0 · Reply

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

Sep 3, 2025, 4:57 PM EDT - 4 weeks ago

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 4 weeks ago

vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 2, 2025, 8:00 AM EDT - 4 weeks ago

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Aug 12, 2025, 4:15 PM EDT - 7 weeks ago

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 8:00 AM EDT - 7 weeks ago

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

Aug 7, 2025, 8:00 AM EDT - 2 months ago

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

Jun 11, 2025, 8:00 AM EDT - 4 months ago

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

May 19, 2025, 9:00 AM EDT - 4 months ago

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 15, 2025, 4:01 PM EDT - 5 months ago

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025, 12:00 PM EDT - 5 months ago

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

Mar 20, 2025, 5:35 PM EDT - 7 months ago

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 17, 2025, 1:59 PM EDT - 7 months ago

FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges

Mar 17, 2025, 8:30 AM EDT - 7 months ago

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Dec 9, 2024, 7:33 AM EST - 10 months ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Dec 2, 2024, 4:05 PM EST - 10 months ago

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

Aug 8, 2024, 4:15 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Jul 26, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Jun 24, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

May 28, 2024, 8:00 AM EDT - 1 year ago

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

May 9, 2024, 4:51 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

Mar 19, 2024, 8:30 AM EDT - 1 year ago

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Mar 13, 2024, 8:00 AM EDT - 1 year ago

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 4, 2024, 8:00 AM EST - 1 year ago

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Mar 1, 2024, 8:00 AM EST - 1 year ago

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

Feb 28, 2024, 8:00 AM EST - 1 year ago

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Feb 22, 2024, 4:00 PM EST - 1 year ago

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Nov 9, 2023, 4:30 PM EST - 2 years ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Nov 8, 2023, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

Nov 2, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Nov 1, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Sep 27, 2023, 8:30 AM EDT - 2 years ago

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

$Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer$

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Sep 18, 2023, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Aug 11, 2023, 4:30 PM EDT - 2 years ago

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Aug 10, 2023, 8:33 AM EDT - 2 years ago

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Jun 16, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Jun 15, 2023, 7:33 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

May 24, 2023, 9:00 AM EDT - 2 years ago

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 11, 2023, 4:15 PM EDT - 2 years ago

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Apr 20, 2023, 8:00 AM EDT - 2 years ago

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

Mar 6, 2023, 5:56 PM EST - 2 years ago

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 6, 2023, 8:02 AM EST - 2 years ago

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases

Feb 27, 2023, 8:02 AM EST - 2 years ago

Cantex Receives FDA "Study May Proceed" Letter for Phase 2 Clinical Trial of Azeliragon for the Treatment of Unmethylated Glioblastoma

Feb 1, 2023, 5:00 PM EST - 2 years ago

Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics

Jan 9, 2023, 8:00 AM EST - 2 years ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

Dec 13, 2022, 8:15 AM EST - 3 years ago

vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer

Nov 10, 2022, 5:25 PM EST - 3 years ago

vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update

Aug 15, 2022, 6:43 PM EDT - 3 years ago

vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update

Jul 27, 2022, 7:00 AM EDT - 3 years ago

vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer

Samiam69 Oct. 3 at 11:26 PM

$VTVT there goes the 650k float 🐢🐢🐢

0 · Reply

AStrokeOfLuck Oct. 3 at 8:52 PM

$VTVT

0 · Reply

Newtrader_covid19 Oct. 3 at 7:10 PM

0 · Reply

Social_Idiot Oct. 2 at 2:13 PM

$VTVT I have to say that I find this stock attractive but between the low float and low volume, the volatility makes it hard to trust.

1 · Reply

Estockpicker Sep. 30 at 3:29 PM

$VTVT interesting stock. what is the catalyst that will drive this stock higher

1 · Reply

Mik21212 Sep. 26 at 6:44 PM

$VTVT in, glta

0 · Reply

dcajic2 Sep. 26 at 2:55 PM

$VTVT Reality land. There are well over 2 million shares outstanding plus if the 80 million investment goes through many more shares will be added

0 · Reply

GDS_investing Sep. 26 at 2:20 PM

$VTVT looking great and strong golden cross is in 50ma vs 200ma = huge long need more volume float only 640k

1 · Reply

outlawinvestor1 Sep. 25 at 9:36 PM

$VTVT

1 · Reply

km1663 Sep. 24 at 10:31 PM

$VTVT it will be interesting to see where the SP goes from here. Looks like a perfect cup has formed on the 6mo time frame.

0 · Reply

GDS_investing Sep. 23 at 2:38 PM

$SSKN great call her glta my followers still huge long now watch $VTVT next very low float only 640k Great company, huge potential and $RFL all for long runup

1 · Reply

GDS_investing Sep. 23 at 10:11 AM

$INVZ told you $SSKN now watch $VTVT float only 640k great company

1 · Reply

JimJames Sep. 19 at 7:16 PM

$VTVT

0 · Reply

km1663 Sep. 19 at 5:45 PM

$VTVT 👀

0 · Reply

Jacks10 Sep. 19 at 4:32 PM

$VTVT what's with the 1 share buys and sells.

0 · Reply

Jacks10 Sep. 19 at 2:59 PM

$VTVT pathetic penny flippers! raise your ask!

0 · Reply

GDS_investing Sep. 19 at 2:58 PM

I will sell half the position at 240 and the rest at 480. LONG and STRONG $VTVT

0 · Reply

GDS_investing Sep. 19 at 1:49 PM

$INVZ AWESOME call here glta my followers sold half position very very nice ! now add long $VTVT (floay only 640k) $SSKN and $RFL

0 · Reply

GDS_investing Sep. 18 at 1:54 PM

$RFL on the move reversal mode looking good need more volume long $RFL and $VTVT $SSKN watch $INTC $HOOD

0 · Reply

dcajic2 Sep. 18 at 11:41 AM

$VTVT Company hasn’t even put out a PR if the 80M private placement has closed. This company still paying a PR person??? This is a company that never follows through. They will announce a conference and never say what exactly happens

0 · Reply

dcajic2 Sep. 18 at 11:40 AM

$VTVT Another 5.5 million shares have been added or will be added with 80 million price placement

0 · Reply

dcajic2 Sep. 17 at 7:53 PM

$VTVT there bare over 2 million shares and growing

0 · Reply

Market Cap	76.99M
Revenue (ttm)	1.02M
Net Income (ttm)	-18.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,809.80%
Debt to Equity Ratio	0.00

Volume	1,200
Avg Vol	3,426
Day's Range	N/A - N/A
Shares Out	3.20M
Stochastic %K	91%
Beta	0.67
Analysts	Sell
Price Target	$35.50